Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study

PHASE2CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Ulcerative ColitisInflammatory Bowel Disease
Interventions
DRUG

Nolpitantium besylate

Trial Locations (14)

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Tallinn

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Singapore

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY